Investing

Cabaletta Bio : CABA

CABA

Stock Data

$2.97

$0.15 (4.82%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Cabaletta Bio Inc is a pioneering biotech firm dedicated to advancing engineered T cell therapies for autoimmune diseases. With a focus on B cell-mediated conditions, its flagship project, DSG3-CAART, targets the autoimmune skin disease mucosal pemphigus vulgaris and is currently in Phase I trials. The company's pipeline also explores treatments for myasthenia gravis and severe autoimmune diseases, among others. Founded in 2017 and based in Philadelphia, Cabaletta Bio collaborates with notable institutions like the University of Pennsylvania and the Children’s Hospital of Philadelphia.